Newron Pharmaceuticals S.p.A. (0QOI.L)
CHF 7.54
(6.95%)
CHF 7.54
(6.95%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 9.05 Million EUR | 48.62% |
| 2022 | 6.09 Million EUR | 5.76% |
| 2021 | 5.76 Million EUR | 16.1% |
| 2020 | 4.96 Million EUR | -11.58% |
| 2019 | 5.61 Million EUR | 111.57% |
| 2018 | 2.65 Million EUR | -80.24% |
| 2017 | 13.42 Million EUR | 228.15% |
| 2016 | 4.09 Million EUR | 266.01% |
| 2015 | 1.11 Million EUR | 3.52% |
| 2014 | 1.08 Million EUR | -66.97% |
| 2013 | 3.27 Million EUR | -63.24% |
| 2012 | 8.89 Million EUR | 3077.14% |
| 2011 | 280 Thousand EUR | -65.26% |
| 2010 | 806 Thousand EUR | -68.29% |
| 2009 | 2.54 Million EUR | -35.37% |
| 2008 | 3.93 Million EUR | -2.26% |
| 2007 | 4.02 Million EUR | 237.87% |
| 2006 | 1.19 Million EUR | 0.0% |
| 2005 | - EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 3.4 Million EUR | 0.0% |
| 2023 Q2 | 5.49 Million EUR | 0.0% |
| 2023 FY | 9.05 Million EUR | 48.62% |
| 2023 Q4 | 3.56 Million EUR | 0.0% |
| 2022 FY | 6.09 Million EUR | 5.76% |
| 2022 Q2 | 2.83 Million EUR | 0.0% |
| 2022 Q4 | 3.26 Million EUR | 0.0% |
| 2021 Q2 | 2.67 Million EUR | 0.0% |
| 2021 Q4 | 3.09 Million EUR | 0.0% |
| 2021 FY | 5.76 Million EUR | 16.1% |
| 2020 FY | 4.96 Million EUR | -11.58% |
| 2020 Q4 | 2.74 Million EUR | 0.0% |
| 2020 Q2 | 2.5 Million EUR | 0.0% |
| 2019 Q4 | 4.8 Million EUR | 0.0% |
| 2019 FY | 5.61 Million EUR | 111.57% |
| 2019 Q2 | 2.23 Million EUR | 0.0% |
| 2018 Q2 | 2 Million EUR | 0.0% |
| 2018 Q4 | 2.01 Million EUR | 0.0% |
| 2018 FY | 2.65 Million EUR | -80.24% |
| 2017 Q2 | 11.68 Million EUR | 0.0% |
| 2017 FY | 13.42 Million EUR | 228.15% |
| 2017 Q4 | 1.74 Million EUR | 0.0% |
| 2016 Q2 | 3.9 Million EUR | 0.0% |
| 2016 FY | 4.09 Million EUR | 266.01% |
| 2016 Q4 | 2.81 Million EUR | 0.0% |
| 2015 FY | 1.11 Million EUR | 3.52% |
| 2015 Q2 | 1.97 Million EUR | 0.0% |
| 2015 Q4 | 401 Thousand EUR | 0.0% |
| 2014 Q4 | 157 Thousand EUR | 0.0% |
| 2014 FY | 1.08 Million EUR | -66.97% |
| 2014 Q2 | 1.4 Million EUR | 0.0% |
| 2013 Q4 | 1.26 Million EUR | 55.08% |
| 2013 FY | 3.27 Million EUR | -63.24% |
| 2013 Q3 | 817.5 Thousand EUR | -60.79% |
| 2013 Q2 | 2.08 Million EUR | 0.0% |
| 2012 Q1 | 2.22 Million EUR | 0.0% |
| 2012 Q2 | 2.22 Million EUR | 0.0% |
| 2012 FY | 8.89 Million EUR | 3077.14% |
| 2012 Q3 | 2.22 Million EUR | 0.0% |
| 2012 Q4 | 817.5 Thousand EUR | -63.24% |
| 2011 Q3 | 70 Thousand EUR | 0.0% |
| 2011 Q1 | 70 Thousand EUR | 0.0% |
| 2011 Q2 | 70 Thousand EUR | 0.0% |
| 2011 FY | 280 Thousand EUR | -65.26% |
| 2011 Q4 | 2.22 Million EUR | 3077.14% |
| 2010 Q3 | 201.5 Thousand EUR | 0.0% |
| 2010 FY | 806 Thousand EUR | -68.29% |
| 2010 Q1 | 201.5 Thousand EUR | 0.0% |
| 2010 Q4 | 70 Thousand EUR | -65.26% |
| 2010 Q2 | 201.5 Thousand EUR | 0.0% |
| 2009 Q4 | 201.5 Thousand EUR | -68.29% |
| 2009 FY | 2.54 Million EUR | -35.37% |
| 2009 Q3 | 635.5 Thousand EUR | 0.0% |
| 2009 Q2 | 635.5 Thousand EUR | 0.0% |
| 2009 Q1 | 635.5 Thousand EUR | 0.0% |
| 2008 Q2 | 983.25 Thousand EUR | 0.0% |
| 2008 Q1 | 983.25 Thousand EUR | 0.0% |
| 2008 FY | 3.93 Million EUR | -2.26% |
| 2008 Q4 | 635.5 Thousand EUR | -35.37% |
| 2008 Q3 | 983.25 Thousand EUR | 0.0% |
| 2007 Q3 | 1 Million EUR | 0.0% |
| 2007 Q2 | 1 Million EUR | 0.0% |
| 2007 Q1 | 1 Million EUR | 0.0% |
| 2007 FY | 4.02 Million EUR | 237.87% |
| 2007 Q4 | 983.25 Thousand EUR | -2.26% |
| 2006 FY | 1.19 Million EUR | 0.0% |
| 2006 Q1 | 297.75 Thousand EUR | 0.0% |
| 2006 Q3 | 297.75 Thousand EUR | 0.0% |
| 2006 Q2 | 297.75 Thousand EUR | 0.0% |
| 2006 Q4 | 1 Million EUR | 237.87% |
| 2005 Q3 | - EUR | 0.0% |
| 2005 Q1 | - EUR | 0.0% |
| 2005 Q2 | - EUR | 0.0% |
| 2005 FY | - EUR | 0.0% |
| 2005 Q4 | 297.75 Thousand EUR | 0.0% |
| 2004 Q4 | - EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Relief Therapeutics Holding AG | -10.85 Million CHF | 183.405% |
| Tecan Group AG | 390.46 Million CHF | 97.68% |
| Santhera Pharmaceuticals Holding AG | 99.54 Million CHF | 90.902% |
| Basilea Pharmaceutica AG | 130.84 Million CHF | 93.078% |
| Bachem Holding AG | 176.96 Million CHF | 94.882% |
| Siegfried Holding AG | 320.4 Million CHF | 97.173% |
| Molecular Partners AG | -40.8 Million CHF | 122.195% |